These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 1416573

  • 1. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
    Lim MJ, Barkan AL, Buda AJ.
    Ann Intern Med; 1992 Nov 01; 117(9):719-26. PubMed ID: 1416573
    [Abstract] [Full Text] [Related]

  • 2. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.
    Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G.
    Clin Endocrinol (Oxf); 2003 Feb 01; 58(2):169-76. PubMed ID: 12580932
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY, Weissberger AJ, Marbach P, Lazarus L.
    Ann Intern Med; 1990 Feb 01; 112(3):173-81. PubMed ID: 2404445
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G.
    J Clin Endocrinol Metab; 2000 Sep 01; 85(9):3132-40. PubMed ID: 10999798
    [Abstract] [Full Text] [Related]

  • 5. Octreotide treatment of acromegaly. A randomized, multicenter study.
    Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM.
    Ann Intern Med; 1992 Nov 01; 117(9):711-8. PubMed ID: 1416572
    [Abstract] [Full Text] [Related]

  • 6. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ, Plöckinger U.
    J Clin Endocrinol Metab; 1989 May 01; 68(5):873-81. PubMed ID: 2565912
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular effects of the somatostatin analog octreotide in acromegaly.
    Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, Harris AG, Lubetzki J.
    Ann Intern Med; 1990 Dec 15; 113(12):921-5. PubMed ID: 2240917
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep 15; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML, Harris AG.
    Arch Intern Med; 1991 Aug 15; 151(8):1573-8. PubMed ID: 1872661
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly.
    Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1999 Jan 15; 84(1):17-23. PubMed ID: 9920056
    [Abstract] [Full Text] [Related]

  • 18. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S, Ren SG, Braunstein GD, Melmed S.
    J Clin Endocrinol Metab; 1991 Aug 15; 73(2):441-3. PubMed ID: 1713220
    [Abstract] [Full Text] [Related]

  • 19. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.
    De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, Cimino V, Maira G, Pontecorvi A, Giustina A.
    Pituitary; 2008 Aug 15; 11(1):13-20. PubMed ID: 17987389
    [Abstract] [Full Text] [Related]

  • 20. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S, Redelmeier DA, Gnehm M, Harris AG.
    J Endocrinol Invest; 1995 May 15; 18(5):364-9. PubMed ID: 7594225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.